Evaluation of the Effectiveness of Interventions on Nephrolithiasis in Transplanted Kidney.

Extracorporeal shock wave lithotripsy Nephrolithiasis Percutaneous nephrolithotomy Renal transplantation Ureteroscopy

Journal

European urology focus
ISSN: 2405-4569
Titre abrégé: Eur Urol Focus
Pays: Netherlands
ID NLM: 101665661

Informations de publication

Date de publication:
May 2023
Historique:
received: 18 06 2022
revised: 08 08 2022
accepted: 16 11 2022
medline: 26 6 2023
pubmed: 26 12 2022
entrez: 25 12 2022
Statut: ppublish

Résumé

De Novo nephrolithiasis in renal transplant can have severe consequences since renal transplantation involves a single functioning kidney with medical and anatomical specificities (heterotopic transplantation on iliac vessels, immunosuppressive treatments, and comorbidities). To systematically review all available evidence on the prevalence of de novo nephrolithiasis in renal transplant, presentation, and stone characteristics, and to report in a meta-analysis the efficacy of stone treatments (extracorporeal shock wave lithotripsy [ESWL], medical treatment, percutaneous nephrolithotomy [PCNL], open surgery, and ureteroscopy). Medline, Embase, and the Cochrane Library were searched up to November 2021 for all relevant publications reporting the management of de novo nephrolithiasis in renal allografts. The primary outcome was stone-free rate (SFR) at 3 mo. Secondary outcomes included prevalence, stone characteristics (size, density, and composition), symptoms on presentation, need for drainage, complications, and recurrence. Data were narratively synthesized in light of methodological and clinical heterogeneity, and a meta-analysis was performed for SFR. The risk of bias of each included study was assessed. We included 37 retrospective studies with 553 patients and 612 procedures; of the 612 procedures 20 were antegrade ureteroscopy, 154 retrograde ureteroscopy, 118 PCNL, 25 open surgery, 155 ESWL, and 140 surveillance/medical treatment. The prevalence of nephrolithiasis in renal transplant was 1.0%. The mean stone size on diagnosis was 11 mm (2-50). The overall SFR at 3 mo was 82%: 96% with open surgery, 95% with antegrade ureteroscopy, 86% with PCNL, 81% with retrograde ureteroscopy, and 75% with ESWL. De novo nephrolithiasis in renal transplant is an infrequent condition. A high SFR were obtained with an antegrade approach (ureteroscopy, PCNL, and open approach) that should be considered in renal transplant patients owing to the heterotopic position of the renal graft. The choice of technique was correlated with stone size: generally ureteroscopy and ESWL for stones 11-12 mm (mean stone size) versus PCNL and open surgery for 17-25 mm stones. De novo nephrolithiasis in renal transplants is an infrequent situation that can have severe consequences on the function of the renal graft. We evaluated the efficacy of each treatment and noted that antegrade approaches (open surgery, percutaneous nephrolithotomy, and antegrade ureteroscopy) were associated with the highest stone-free rate. As opposed to the management of nephrolithiasis in native kidney, an antegrade approach should be considered more in renal transplant patients.

Identifiants

pubmed: 36567234
pii: S2405-4569(22)00278-4
doi: 10.1016/j.euf.2022.11.019
pii:
doi:

Types de publication

Journal Article Meta-Analysis Review Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

491-499

Informations de copyright

Copyright © 2022. Published by Elsevier B.V.

Auteurs

Romain Boissier (R)

Aix-Marseille University, Marseille, France; Department of Urology & Renal Transplantation, La Conception University Hospital, Assistance-Publique Marseille, France.

Oscar Rodriguez-Faba (O)

Department of Urology, Fundacion Puigvert, University Autonoma of Barcelona, Barcelona, Spain.

Rhana Hassan Zakri (RH)

Department of Urology & Renal Transplantation Guy's and St Thomas' Hospital, London, UK.

Vital Hevia (V)

Urology Department, Hospital Universitario Ramón y Cajal, Alcalá University, Madrid, Spain.

Klemens Budde (K)

Department of Nephrology, Charité Universitätsmedizin Berlin, Berlin, Germany.

Arnaldo Figueiredo (A)

Department of Urology and Renal Transplantation, Coimbra University Hospital, Coimbra, Portugal.

Enrique Lledó García (EL)

Department of Urology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.

Jonathon Olsburgh (J)

Department of Urology & Renal Transplantation Guy's and St Thomas' Hospital, London, UK.

Heinz Regele (H)

Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria.

Cathy Yuhong Yuan (CY)

Department of Medicine, Health Science Centre, McMaster University, Hamilton, Ontario, Canada.

Alberto Breda (A)

Department of Urology, Fundacion Puigvert, University Autonoma of Barcelona, Barcelona, Spain. Electronic address: albbred@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH